Health Care [ 7/12 ] | Biotechnology [ 39/74 ]
NASDAQ | Common Stock
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines.
The company offers ZURZUVAE, a neuroactive steroid positive allosteric modulator of GABA receptors targeting synaptic and extrasynaptic GABA receptors for the treatment of postpartum depression in adults.
Its product pipeline also includes SAGE-324, a novel GABA receptor positive allosteric modulator for chronic oral dosing, including seizures in developmental and epileptic encephalopathies; and SAGE-319, an extrasynaptic-preferring GABA receptor positive allosteric modulator PAM for treating behavioral symptoms associated with neurodevelopmental disorders.
In addition, the company is developing various product candidates, including SAGE-817 and SAGE-039 for the treatment of acute and chronic brain health disorders, including work on allosteric modulation of the GABA and NMDA receptor systems in the brain, as well as NMDA receptor negative allosteric modulator focusing on the treatments for neurodevelopmental disorders.
The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011.
Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 12, 25 | -1.20 Increased by +33.50% | -1.36 Increased by +11.69% |
| Oct 29, 24 | -1.53 Increased by +54.60% | -1.53 |
| Jul 31, 24 | -1.70 Increased by +36.57% | -1.66 Decreased by -2.41% |
| Apr 25, 24 | -1.80 Increased by +26.83% | -1.65 Decreased by -9.09% |
| Feb 14, 24 | -1.80 Increased by +27.13% | -1.28 Decreased by -40.63% |
| Nov 7, 23 | -3.37 Decreased by -45.89% | -2.73 Decreased by -23.44% |
| Aug 7, 23 | -2.68 Decreased by -25.82% | -2.55 Decreased by -5.10% |
| May 2, 23 | -2.46 Decreased by -18.84% | -2.50 Increased by +1.60% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 12.82 M Decreased by -83.56% | -95.78 M Decreased by -192.85% | Decreased by -747.33% Decreased by -1.68 K% |
| Sep 30, 24 | 11.87 M Increased by +337.08% | -93.55 M Increased by +53.60% | Decreased by -788.06% Increased by +89.38% |
| Jun 30, 24 | 8.65 M Increased by +249.80% | -102.85 M Increased by +35.85% | Decreased by -1.19 K% Increased by +81.66% |
| Mar 31, 24 | 7.90 M Increased by +139.89% | -108.48 M Increased by +21.49% | Decreased by -1.37 K% Increased by +67.27% |
| Dec 31, 23 | 77.97 M Increased by +2.62 K% | -32.71 M Increased by +75.47% | Decreased by -41.95% Increased by +99.10% |
| Sep 30, 23 | 2.72 M Increased by +56.18% | -201.63 M Decreased by -56.26% | Decreased by -7.42 K% Decreased by -0.05% |
| Jun 30, 23 | 2.47 M Increased by +64.82% | -160.32 M Decreased by -31.40% | Decreased by -6.48 K% Increased by +20.28% |
| Mar 31, 23 | 3.29 M Increased by +108.22% | -138.19 M Decreased by -15.40% | Decreased by -4.20 K% Increased by +44.58% |